1
|
Herb-drug interactions: a literature review.
|
Drugs
|
2005
|
2.59
|
2
|
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
|
Clin Pharmacokinet
|
2005
|
1.75
|
3
|
St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
|
Toxicol Appl Pharmacol
|
2006
|
1.60
|
4
|
Clinical pharmacogenetics and potential application in personalized medicine.
|
Curr Drug Metab
|
2008
|
1.29
|
5
|
Drug bioactivation, covalent binding to target proteins and toxicity relevance.
|
Drug Metab Rev
|
2005
|
1.17
|
6
|
Pharmacokinetic interactions of drugs with St John's wort.
|
J Psychopharmacol
|
2004
|
1.15
|
7
|
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
|
Curr Drug Metab
|
2004
|
1.15
|
8
|
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
|
AAPS J
|
2009
|
1.08
|
9
|
Human multidrug resistance associated protein 4 confers resistance to camptothecins.
|
Pharm Res
|
2005
|
1.01
|
10
|
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
|
Mol Cancer Ther
|
2009
|
0.98
|
11
|
Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
|
Curr Drug Metab
|
2007
|
0.98
|
12
|
Insights into the structure, function, and regulation of human cytochrome P450 1A2.
|
Curr Drug Metab
|
2009
|
0.96
|
13
|
Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.
|
Br J Clin Pharmacol
|
2006
|
0.96
|
14
|
Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.
|
Eur J Pharm Sci
|
2006
|
0.95
|
15
|
ADME properties of herbal medicines in humans: evidence, challenges and strategies.
|
Curr Pharm Des
|
2011
|
0.91
|
16
|
Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation.
|
Int J Oncol
|
2003
|
0.91
|
17
|
Topotecan is a substrate for multidrug resistance associated protein 4.
|
Curr Drug Metab
|
2006
|
0.90
|
18
|
Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice.
|
Immunol Invest
|
2005
|
0.90
|
19
|
A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese.
|
Curr Drug Metab
|
2007
|
0.89
|
20
|
Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese.
|
Eur J Pharm Sci
|
2006
|
0.88
|
21
|
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
|
J Pharmacol Exp Ther
|
2006
|
0.88
|
22
|
Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese.
|
Pharm Res
|
2006
|
0.87
|
23
|
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
|
Ther Clin Risk Manag
|
2005
|
0.87
|
24
|
Transport of thalidomide by the human intestinal caco-2 monolayers.
|
Eur J Drug Metab Pharmacokinet
|
2005
|
0.85
|
25
|
Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
|
Eur J Pharm Sci
|
2005
|
0.85
|
26
|
Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene.
|
Drug Metab Dispos
|
2006
|
0.84
|
27
|
Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer.
|
J Med Food
|
2005
|
0.84
|
28
|
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
|
Pharm Res
|
2005
|
0.83
|
29
|
The very C-terminus of protein kinase Cepsilon is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1.
|
Cell Signal
|
2005
|
0.83
|
30
|
Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.83
|
31
|
Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.
|
Eur J Pharm Biopharm
|
2011
|
0.83
|
32
|
Tanshinone IIB, a primary active constituent from Salvia miltiorrhza, exhibits neuro-protective activity in experimentally stroked rats.
|
Neurosci Lett
|
2007
|
0.83
|
33
|
Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats.
|
J Med Food
|
2004
|
0.83
|
34
|
Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.
|
AAPS J
|
2009
|
0.83
|
35
|
Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
0.83
|
36
|
Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
|
J Liposome Res
|
2011
|
0.81
|
37
|
Is a standard fixed dose of mycophenolate mofetil ideal for all patients?
|
Nephrol Dial Transplant
|
2007
|
0.81
|
38
|
Predicting pharmacokinetic herb-drug interactions.
|
Drug Metabol Drug Interact
|
2004
|
0.81
|
39
|
Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats.
|
Curr Drug Metab
|
2006
|
0.81
|
40
|
The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling.
|
Cell Signal
|
2006
|
0.80
|
41
|
Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
|
Curr Drug Metab
|
2006
|
0.80
|
42
|
Novel agents that potentially inhibit irinotecan-induced diarrhea.
|
Curr Med Chem
|
2005
|
0.79
|
43
|
Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat.
|
J Pharm Biomed Anal
|
2005
|
0.79
|
44
|
Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra.
|
Pharm Res
|
2007
|
0.79
|
45
|
A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia.
|
J Med Food
|
2005
|
0.79
|
46
|
Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.
|
Eur J Pharm Sci
|
2002
|
0.79
|
47
|
Enantioseparation of warfarin and its metabolites by capillary zone electrophoresis.
|
Electrophoresis
|
2003
|
0.78
|
48
|
Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.
|
Eur J Pharm Sci
|
2003
|
0.78
|
49
|
Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
0.78
|
50
|
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
|
Curr Drug Metab
|
2007
|
0.78
|
51
|
Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.
|
Pharm Res
|
2002
|
0.78
|
52
|
Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.
|
Pharm Res
|
2005
|
0.77
|
53
|
Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
|
Drug Metab Dispos
|
2007
|
0.77
|
54
|
Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.77
|
55
|
Pharmacokinetics of recombinant human endostatin in rats.
|
Curr Drug Metab
|
2006
|
0.77
|
56
|
Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
|
J Clin Pharmacol
|
2009
|
0.76
|
57
|
Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes.
|
Curr Drug Metab
|
2005
|
0.75
|
58
|
Chiral CE separation of warfarin in albumin containing samples.
|
J Pharm Biomed Anal
|
2002
|
0.75
|
59
|
Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin.
|
Pharm Res
|
2005
|
0.75
|
60
|
Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
|
J Clin Pharmacol
|
2013
|
0.75
|
61
|
Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.75
|
62
|
Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug.
|
Ther Drug Monit
|
2013
|
0.75
|
63
|
Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes.
|
Curr Drug Metab
|
2005
|
0.75
|
64
|
Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection.
|
J Pharm Biomed Anal
|
2007
|
0.75
|
65
|
Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.75
|
66
|
Structural identification of a new acetildenafil analogue from pre-mixed bulk powder intended as a dietary supplement.
|
Food Addit Contam
|
2006
|
0.75
|